Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in ...